xken health - from a urine sample
deciphers your health and your true age

Biological age corresponds to the chronological age of the body, combined with the accumulated external influences (e.g. air pollution, diet, etc.) on your health. BioAge is an important component of xken health and determines your current state of health, expressed in your biological age. The further development of your health (LifeSpeed) and therefore your life expectancy is also determined from the sample.

If your biological age is higher than your lifespan, this is an indication that pathological (disease-related) processes are taking place in your body and demonstrates the urgency of taking appropriate therapeutic measures. Biological age can be changed in both directions! Age-associated diseases are detected, such as fibrosis, which is caused by inflammation, environmental influences, and contaminated food. With early detection, you can change your lifestyle, adjust your diet and exercise, or use targeted medication. The success of appropriate measures can be xken health be monitored at regular intervals at any time and their individual therapy adjustment can be made.

Air pollution shortens the biological age of an average 50-year-old by more than two years. Therefore, air pollution is expected to have an even greater impact on older people.
In the study* funded by the EU Commission, the developed biological age of 660 participants was examined using proteomic analysis to determine their response to air pollution.

In connection with chronic diseases, an additional negative impact on biological age and a reduced lifespan is to be expected.

The rate of aging can be influenced. Organize your healthy life now!

Read more in the following studies:

• Martens DS et al.Urinary peptidomic profiles to address age-related disabilities: a prospective population study.Lancet Healthy Longev. 2021, 2(11):e690-e703.
• Martens DS et al.Association of Air Pollution with a Urinary Biomarker of Biological Aging and Effect Modification by Vitamin K in the FLEMENGHO Prospective Population Study.Environmental Health Perspective. 2023, 131(12):127011. (*)

The component BioHealth covers up to 70% of all causes of disease! Disease-related changes in heart (HeartRisk) and kidneys (KidneyRisk) in order to treat them successfully and in a timely manner. Changes in these organs must be detected and treated early to prevent them from becoming chronic.
‍
The kidneys and heart are the central organs. Environmental damage and contaminated food chains affect the human body, which reacts with inflammation, resulting in the formation of fibrosis. This is also the basis of all chronic diseases. The real dilemma: Chronic diseases are currently only diagnosed when organ damage is massively advanced. At that point, medication can no longer even halt the progression of organ damage, or even slow it down. No medication has any effect on dead organ cells; the condition is irreparable. The suffering caused by the consequences of the disease, such as heart attacks, dialysis, and premature death, is no longer preventable. Life expectancy can be shortened by 20 years or more. Leading physicians and scientists have demonstrated the benefits of the test in numerous studies.

xken health detects fibrotic changes that lead to heart failure, coronary heart disease or chronic kidney disease very early and can avert the effects of the diseases, i.e. organ damage, through timely, targeted therapies.

From Molecular Analysis to Personalised Therapy

Molecular analysis of the patient’s proteome lays the foundation for a new approach to personalised therapy selection. Based on individual molecular information and existing database knowledge, different therapeutic approaches can be evaluated in silico, and their potential effects on the patient’s individual molecular profile can be simulated. The importance of such personalised therapy selection is particularly evident in patients with high blood pressure. A significant proportion of patients are inadequately or suboptimally controlled by their current medication. A key reason is that treatment decisions are often based on clinical parameters and population-based recommendations, while the individual molecular changes of each patient are not sufficiently taken into account.

This is where BioHealth comes in: proteomic information makes it possible not only to determine whether health-related changes are occurring, but also which molecular processes are affected in each individual patient. This enables therapeutic measures to be selected more precisely according to the patient’s individual biological state.

Read more in exemplary studies:

• Tofte N et al. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomized placebo-controlled trial. Lancet Diabetes Endocrinol. 2020.
• Htun NM et al. Prediction of acute coronary syndromes by urinary proteome analysis.PLoS One. 2017.
• Zhang ZY et al. Urinary Proteome and Systolic Blood Pressure as Predictors of 5-Year Cardiovascular and Cardiac Outcomes in a General Population.Hypertension 2015.
• Latosinska A, et al. In silico prediction of optimal multifactorial intervention in chronic kidney disease. J Transl Med 2025;23(1):943.
• Jaimes Campos MA et al. Prognosis and personalized in-silico prediction of treatment efficacy in cardiovascular and chronic kidney disease: a proof-of-concept study. Pharmaceuticals (Basel) 2023;16:1298.

Cell repair and renewal processes are constantly taking place in your body. In a healthy and balanced state of health, your body usually identifies and corrects errors. Disturbances, such as inflammatory processes caused by environmental stress, etc., can upset this balance, with the possible consequence of uncontrolled cell growth!

OncoRisk detects these changes at the protein level, which often precede tumors. Then, through lifestyle changes, such as dietary changes, the basis for cancer can be removed.

Of most cancers, only a few are aggressive and beyond control. Nevertheless, if the cancer is localized and has manifested in an organ, proteomic analysis provides precise diagnostics based on the proteome, even for particularly common cancers, as part of this health test for bladder and prostate cancer.

Read more in the following study:

• Belczacka I, et al.Urinary CE-MS peptide marker pattern for detection of solid tumors.Sci Rep. 2018.

How does proteome analysis work? - simply explained -